Investigational drug · Phase 2
SPVN06
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Retinitis Pigmentosa.
Phase 2Last checked: Nov 19, 2026Latest source record: May 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "SPVN06"
First trial start
2023
Apr 12, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPVN06", any sponsor or status.
Conditions studied
As listed on its trial records.
- Retinitis Pigmentosa
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "SPVN06" as an intervention, largest first.
- Promising ROd-cone DYstrophy Gene therapYActive, not recruiting
SparingVisionIndustry
NCT05748873 · 33 participants · Start Apr 12, 2023 · Primary completion Feb 2027
Drug: SPVN06 · For: Retinitis Pigmentosa
Sites: Miami, Florida; Boston, Massachusetts; Portland, Oregon · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical safety and biodistribution of SPVN06, a novel gene- and mutation-independent gene therapy for rod-cone dystrophies.
Marie M, Churet L, Gautron AS, et al. · Gene Ther 2026
- Genetic Therapies for Retinitis Pigmentosa: Current Breakthroughs and Future Directions.
Pniakowska Z, Dzieża N, Kustosik N, et al. · J Clin Med 2025
Also in development for Retinitis Pigmentosa
- BS01Phase 22 trials
Bionic Sight LLC · Retinitis Pigmentosa, Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
- CPK850Phase 21 trial
Novartis · Retinitis Pigmentosa
- famzeretcelhuman retinal progenitor cells, jCellPhase 21 trial
jCyte, Inc · Retinitis Pigmentosa
- KIO-301Phase 21 trial
Kiora Pharmaceuticals, Inc. · Retinitis Pigmentosa
- OCU400Phase 21 trial
Ocugen · Retinitis Pigmentosa, Leber Congenital Amaurosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.